Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrigAMI-4: Amivantamab With or Without Other Agents in Head and Neck Squamous Cell Carcinoma
jRCT2031250006Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of amivantamab in head and neck squamous cell carcinoma (HNSCC) (7 cohorts), sponsored by Janssen Pharmaceutical. Started May 2025; status: active, not recruiting.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031250006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250006.